1167P - Melanoma Brain Metastases Patients Treated with Stereotactic Radiosurgery and Ipilimumab versus Stereotactic Radiosurgery Alone: A Systematic Revie...

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Cancers in Adolescents and Young Adults (AYA)
Skin cancers
Surgical oncology
Radiation oncology
Presenter Steven Nguyen
Citation Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376
Authors S.M. Nguyen1, A. Castrellon2, O. Vaidis3, A. Johnson4
  • 1College Of Medicine, University of Central Florida, 32832 - Orlando/US
  • 2Breast Cancer Center, Memorial Cancer Institute, 33021 - Hollywood/US
  • 3Department Of Mathematics & Statistics, University of South Florida, 33620 - Tampa/US
  • 4Department Of Computer Science, University of Houston, 77204 - Houston/US



The synergistic effects of radiotherapy and novel immunotherapy agents have shown renewed interest in cancer management. We examined survival outcomes in melanoma brain metastases (MBM) patients treated with stereotactic radiosurgery (SRS) and ipilimumab immunotherapy. We compared these outcomes with those of MBM patients receiving SRS without added immunotherapy.


We conducted the first systematic review with meta-analysis of studies comparing combined SRS and ipilimumab with SRS only in MBM. The protocol was published in the PROSPERO register for systematic reviews. MEDLINE and CENTRAL databases were searched using PRISMA method by three separate reviewers. Studies that examined SRS and ipilimumab compared to SRS without ipilimumab in MBM were included. Newcastle-Ottawa Scale Risk of Bias Assessment and the GRADE evidence quality rating method were used for qualitative appraisal. Statistical analysis was performed using Review Manager.


We found 37 publications in our search and identified 4 retrospective studies to further assess; 3 studies were chosen for pooled-analysis. Evidence for survival benefits with combined treatment was rated “low”, per GRADE method. Meta-analysis of 222 patients confirmed significant survival advantage for SRS and ipilimumab (pooled median survival: 16.8 vs. 6.2 months; HR 0.38, 95% CI: [0.28 – 0.52]; p 


Combining stereotactic radiosurgery and ipilimumab in melanoma brain metastases can dramatically improve survival rate compared to stereotactic radiosurgery without immunotherapy. There is no increased risk of radiation necrosis and/or intracranial bleeding with combining radiation and immunotherapy in this setting.

Clinical trial identification

Legal entity responsible for the study

University of Central Florida College of Medicine




All authors have declared no conflicts of interest.